Results 281 to 290 of about 1,119,690 (306)

Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back

Ca-A Cancer Journal for Clinicians, 2014
Giada Bianchi, Kenneth C Anderson
exaly  

Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic response

Lancet, The, 2000
Zuzana Diamant, Ashwini K Mathur, Ratko Djukanovic   +2 more
exaly  

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Lancet, The, 2008
Alexa B Kimball, Ka Papp
exaly  

Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis

Lancet, The, 1999
Anthony Weetman, Geoff Hale, Herman Waldmann   +2 more
exaly  

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet, The, 2015
Iain B Mcinnes, Philip J Mease, Bruce W Kirkham   +2 more
exaly  

Monoclonal Antibody 5F11G11

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2017
openaire   +2 more sources

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

Lancet, The, 2008
Ka Papp, Kristian Reich
exaly  

Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock

Lancet, The, 1998
Robert Baughman
exaly  

Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets

Lancet, The, 2004
Jan Ter Meulen, Bart L Haagmans, Thijs Kuiken   +2 more
exaly  

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

Lancet, The, 2016
J Mark Fitzgerald, Eugene R Bleecker, Parameswaran Nair   +2 more
exaly